|
|
Blood, Vol. 111, Issue 4, 1834-1839, February 15, 2008
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
Blood le Coutre et al.
111: 1834
Supplemental materials for: le Coutre et al
In addition to those investigators listed as authors, the following individuals participated as investigators in this trial: Austria: Peter Valent, University Klinik fur Innere Medizin I, Wein
Belgium: Philippe Martiat, Institut Jules Bordet, Bruxelles
Canada: Jeffrey Lipton, Princess Margaret Hospital, Ontario France: Francois Guilhot, CHU La Miletrie, Poitiers
Thierry Facon, Hôpital Claude Huriez, Lille
Franck-Emmanuel Nicolini, Hôpital Edouard Herriot, Lyon
Michel Tulliez, Hôpital Henri Mondor, Créteil
Germany: Thomas Fischer, III. Medizinische Klinik der Universität Mainz, Mainz
Dietger W. Niederwieser, University Hospital Leipzig, Leipzig
Justus Duyster, III. Med. Klinik & Poliklinik der TU München, München
Tim Bruemmendorf, University-Klinikum Eppendorf, Hamburg
Hong Kong: Yok-lam Kwong, Queen Mary Hospital, Pokfulam Italy: Orbassano
Giuliana Alimena, Azienda Policlinico Umberto I - Università La Sapienza, Roma
Enrica Morra, Azienda Ospedaliera Niguarda Ca’ Granda, Milano
Mario Lazzarino, Policlinico S. Matteo-IRCCS Università degli Studi di Pavia, Pavia
Francesco Nobile, Ospedali Riuniti Az. Osp. Bianchi, Melacrino e Morelli, Reggio Calabria
Marco Gobbi, Università degli Studi Genova Az. Osp. Ospedale S. Martino, Genova
Enrico Pogliani, Ospedale San Gerardo, Monza
Bruno Rotoli, Policlinico-Universita degli Studi Federico III, Napoli
The Netherlands: G.J. Ossenkoppele, VU Medisch Centrum, Amsterdam New Zealand: Peter Browett, The University of Auckland, Auckland Poland: Lech Konopka, KL. Chorob Wewnetrznych Ins. Hematologii I Transfuzjologii, Warszawa
Jerzy Holowiecki, Slaska Akademia Medyczna w Katowicach, Katowice
Tadeusz Robak, Uniwersytet Medyczny w Lodzi, Lodz
Republic of Korea: Sang-Kyun Sohn, Kyung Pook National University Hospital, Taegu
Singapore: Charles Chuah, Singapore General Hospital, Singapore
Spain: Francisco Cervantes, Hospital Clinic I Provincal de Barcelona, Barcelona
Sweden: Johan Richter, Hematologimottagningen, Universitetssijukhuset, Lund Switzerland: Yves Chalandon, Hopitaux Universitaires de Geneve, Geneve Taiwan: Ching-Yuan Kuo, Chang Gung Memorial Hospital, Kaohsiung United Kingdom: Richard Clark, Royal Liverpool University Hospital, Liverpool
Graeme Smith, Leeds General Infirmary, Leeds
Charles Craddock, Queen Elizabeth Hospital Institute of Cancer Studies, Birmingham
Tessa Holyoake, Glasgow Royal Infirmary, Glasgow United States: Jeffrey Lancet, H Lee Moffitt Cancer Center, Tampa, FL
Ronald Hoffman, University of Illinois at Chicago, Chicago, IL
Martha Wadleigh, Dana Farber Cancer Institute, Boston, MA
Charles Schiffer, Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, MI
Harry Erba, University of Michigan, Ann Arbor, MI
Bayard L. Powell, Wake Forest University, Winston-Salem, NC
B. Douglas Smith, Sidney Kimmel Comprehensive Cancer Ctr, John Hopkins, Baltimore, MD
Ravi Bhatia, City of Hope Comprehensive Cancer Center, Duarte, CA
Jane L. Liesveld, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY
Madan H. Jagasia, Vanderbilt University Medical Center, Nashville TN
Stuart L. Goldberg, Hackensack University Medical Center, Hackensack, NJ Mutational analysis
D.W. Kim, Andreas Hochhaus, Giovanni Martinelli, Giuseppe Saglio, Jerald Radich, Yaping Shou, and Timothy Hughes participated in mutational analysis for this study.
|
|
